NEW YORK, Feb. 26 /PRNewswire-FirstCall/ -- NeoStem, Inc. (Amex: NBS), which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, today announced that the Company is scheduled to present at the 3rd Annual Stem Cell Summit in New York City on Tuesday, February 26, 2008.
The Annual Stem Cell Summit is organized and produced by RRY Publications and Robin Young Consulting. This year's Summit will feature more than 50 speakers, including a panel of stem cell patients. The goal of the Summit is to bring together investors, industry executives, practitioners and analysts to learn about investment opportunities in the stem cell marketplace, groundbreaking stem cell products physicians are using today, and the growing market potential in terms of revenues. For additional information or to register, please visit http://www.stemcellsummit.com.
Wayne A. Marasco, MD, Ph.D., NeoStem Inc. Cofounder and Chairman of the Scientific Advisory Board will give a brief presentation on the Company's proprietary Very Small Embryonic Like Stem Cells (VSELs) technology. VSELs have been identified in adult bone marrow and resemble embryonic stem cells both morphologically and transcriptionally. Although early stage technology, the Company expects VSELS to serve as the basis for its entry into the therapeutic market place.
VSELs have the ability to grow in the laboratory and multiply into clusters of cells that then can differentiate into specialized cells found in different types of tissue including cardiac, neural, endothelial, muscle, pancreatic and hematopoietic cells. However, unlike controversial embryonic stem cells, VSELs can be harvested from adult peripheral blood. These naturally occurring regenerative cells may have the potential to be used for future therapeutic repair of degenerative, diseased or damaged tissue.
About NeoStem, Inc.
NeoStem is managing a growing nationwide network of adult stem cell collection centers, enabling people to donate and store their own (autologous) stem cells when they are young and healthy for their personal use in times of future medical need. The Company has also recently entered the research and development and therapeutic arenas, through the acquisition of a worldwide exclusive license to an early-stage technology to identify and isolate rare stem cells from adult human bone marrow, called VSELs (very small embryonic- like stem cells), which have been shown to have several physical characteristics that are generally found in embryonic stem cells.
Certain statements in this press release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform
Act of 1995, including statements concerning the ability of NeoStem, Inc.
("the Company") to develop the adult stem cell business, to develop the
VSEL technology, the future of regenerative medicine and the role of adult
stem cells and VSELs in that future, the future use of adult stem cells and
VSELs as a treatment option and the potential revenue growth of the
Company's business. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors, which may cause the actual
results, performance or achievements of the Company, or industry results,
to be materially different from any future results, performance, or
achievements expressed or implied by such forward-looking statements. The
Company's ability to enter the adult stem cell arena, its success in such
arena and future operating results are dependent upon many factors,
including but not limited to (i) the Company's ability to obtain sufficient
capital or a strategic business arrangements to fund its expansion plans;
(ii) the Company's ability to build the management and human resources and
infrastructure necessary to support the growth of its business; (iii)
competitive factors and developments beyond the Company's control; (iv)
scientific and medical developments beyond the Company's control; (v) the
Company's inability to obtain appropriate state licenses or any other
adverse effect or limitations caused by government regulation of the
business; (vi) whether any of the Company's current or future patent
applications result in issued patents; and (vii) other risk factors
discussed in the Company's periodic filings with the Securities and
Robin Smith, Chief Executive Officer, 212-584-4180
|SOURCE NeoStem, Inc.|
Copyright©2008 PR Newswire.
All rights reserved